ORIFARM A/S — Financial report

CVR 26058708

Latest financial period

  • 2025 • 2025-01-01 • 2025-12-31 • entity • DKK • 1174659000 • 23018000 • 14207000 • 9727000 • 148121000 • 44048000 • 37

Financial history

  • 2024 • 2024-01-01 • 2024-12-31 • entity • DKK • 1223777000 • 23231000 • 15295000 • 14865000 • 150368000 • 53921000 • 38
  • 2023 • 2023-01-01 • 2023-12-31 • entity • DKK • 1575946000 • 27635000 • 15762000 • 18874000 • 301842000 • 76256000 • 37
  • 2022 • 2022-01-01 • 2022-12-31 • entity • DKK • 1404798000 • 20155000 • 14047000 • 9941000 • 421634000 • 57382000 • 34
  • 2021 • 2021-01-01 • 2021-12-31 • entity • DKK • 1493622000 • 19490000 • 14096000 • 8190000 • 195390000 • 47442000 • 40
  • 2020 • 2020-01-01 • 2020-12-31 • entity • DKK • 1180912000 • 35447000 • 10634000 • 6563000 • 195124000 • 42252000 • 42
  • 2019 • 2019-01-01 • 2019-12-31 • entity • DKK • 1200155000 • 31438000 • 8961000 • 5096000 • 175252000 • 35689000 • 38
  • 2018 • 2018-01-01 • 2018-12-31 • entity • DKK • 1250457000 • 36221000 • 7288000 • 4295000 • 194205000 • 40593000 • 45
  • 2017 • 2017-01-01 • 2017-12-31 • entity • DKK • 1192494000 • 34473000 • 7607000 • 4424000 • 232009000 • 36298000 • 42

Annual report highlights

  • primary activities • Orifarm A/S is part of Orifarm Group, which is a dynamic international player in the healthcare business.​ ​Orifarm A/S is selling Parallel Imported pharmaceuticals in Denmark. Pharmaceuticals are bought in EU/EEA members with low prices and then re-packed, imported and sold in other EU/EEA markets with higher prices.​​Pharma Trade is also active in Clinical Trials Supply and sales of Unlicensed pharmaceuticals. • entity
  • development in activities and financial affairs • Development in activities and financesOrifarm A/S’ revenue decreased by 4.0% to mDKK 1,175 (2024: mDKK 1,224), while the market share decreased by​0.2 pp to 45.1%. ​ ​Orifarm A/S’ operating margin decreased to 1.21% (2024: 1.25 %). • entity
  • development in activities and financial affairs • Development in activities and finances Orifarm A/S’ revenue decreased by 4.0% to mDKK 1,175 (2024: mDKK 1,224), while the market share decreased by​0.2 pp to 45.1%. ​ ​Orifarm A/S’ operating margin decreased to 1.21% (2024: 1.25 %). • entity
  • expected development • For 2026, Orifarm A/S expects to increase revenue and operating income compared to 2025 level.​​Risk ​Operating conditions ​To a significant extent, the Group’s consolidated earnings depend on legislative measures that influence pharmaceutical pricing in both the purchase and sales countries. ​ ​In the Pharma Trade business area, products generally need to be re packed to meet regulatory requirements in the import countries. This includes translating mandatory packaging text, replacing the package leaflet, and often adjusting pack sizes. These steps require lawful changes to the original packaging and therefore relate to trademark protection. Orifarm’s policy is to respect trademark rights; however, originators frequently use trademark law to limit parallel imports, making disputes and litigation common in this area. ​ ​Financial matters ​Orifarm A/S’ financial risks, including its cash management and extension of credits, are managed at a corporate level to ensure a balanced risk profile. • entity
  • result compared with expectations • Profit/loss for the year in relation to expected developmentsOrifarm A/S’ result for 2025 amounts to mDKK 9.7 (2024: mDKK 14.9), which is lower than expectations mainly due to decreased net financials. • entity
  • result compared with expectations • Profit/loss for the year in relation to expected developments Orifarm A/S’ result for 2025 amounts to mDKK 9.7 (2024: mDKK 14.9), which is lower than expectations mainly due to decreased net financials. • entity
  • subsequent events • No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report. • entity
  • contingent liabilities • The Entity participates in a Danish joint taxation arrangement where HBS Capital ApS serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is​therefore liable for income taxes etc. for the jointly taxed entities, and for obligations, if any, relating to the withholding of tax on interest, royalties and dividend for the jointly taxed entities. The jointly taxed entities' total known net liability under the joint taxation arrangement is disclosed in the administration company's financial statements.​​The Entity has normal trade obligations on returned goods, and no significant losses are expected. • entity
  • mortgages collateral • 12 Assets charged and collateralThe Entity has provided guarantees under which the guarantors assume joint and several liability for Group ​enterprises' net debt with bank and credit institutions. The Group's total net debt in relation to this guarantee ​is booked at DKK 125.1m per 31 December 2025. • entity
  • mortgages collateral • 12 Assets charged and collateral The Entity has provided guarantees under which the guarantors assume joint and several liability for Group ​enterprises' net debt with bank and credit institutions. The Group's total net debt in relation to this guarantee ​is booked at DKK 125.1m per 31 December 2025. • entity